Kornimate/medical-research-clean huggingface dataset:
decreasing trigger sensitivity could assist peep to further improve regional ventilation distribution

Conditions: Mechanical Ventilation

Summary: in mechanically ventilated patients during supine position, alveolar collapse usually distributes in dependent lung region.decrease of flow trigger sensitivity might improve homogeneous of tidal volume distribution.

in mechanically ventilated patients during supine position, alveolar collapse usually distributes in dependent lung region. high positive end expiratory pressure (peep) has been applied to improve the homogeneous distribution of ventilation by increasing the end expiratory lung ventilation (eelv) and alveolar recruitment. however, for patients who increasing peep in some extent still existed poor aeration in the dependent region, further elevating peep seems to be unreasonable that perhaps lead to overdistension. decreasing trigger sensitivity might further evoke inspiratory efforts to improve the ventilation for this type of patients.the electrical impedance tomography (eit) was applied in monitoring the regional ventilation distribution at the bedside.

Eligibility criteria:
inclusion criteria: 1. the post operative patients who received pressure support ventilation; 2. after the clinical peep was evaluated 5cmh2o, the tidal volume distribution still existed heterogeneity. exclusion criteria: 1. under 18 years; 2. history of diaphragm dysfunction and surgery; 3. central respiratory drive dysfunction; 4. history of esophageal, gastric or lung surgery; 5. the contraindication of using eit (pacemaker, defibrillator, and implantable pumps).
addition of gonadotropin releasing hormone agonist to luteal phase support

Conditions: Female Infertility

Summary: hormonal milieu during implantation is crucial to embryo-endometrium interaction and to the viability of the conceptus. alterations in the peri-implantation environment are considered to impair perinatal outcomes in intracytoplasmic sperm injection (icsi) therapy. gnrh-a is a new and promising modality for lps. regimens for using gnrh-a in lps, including single mid-luteal bolus or the addition of a gnrh-a to progesterone supplementation, have been recently suggested. the aim of this study is to evaluate the impact of addition of mid-luteal single-dose or multiple-dose gnrh agonist to the routine luteal phase support in patients undergoing icsi cycles using gnrh antagonist protocol.


Eligibility criteria:
inclusion criteria: 1. patient age ≤ 38 years. 2. bmi ≤ 30. 3. basal follicle stimulating hormone (fsh) level ≤ 10 iu/l. 4. anti-müllerian hormone (amh): ≤ 5 ng/ml. exclusion criteria: 1. endometriosis. 2. polycystic ovarian syndrome (pcos). 3. uterine pathology or anomaly. 4. evidence of hydrosalpinx by hysterosalpingography or ultrasound. 5. comorbidities: diabetes mellitus, hypertension, immune diseases.

Keywords: luteal phase support, icsi, gonadotropin releasing hormone agonist
a phase 2 study of tarceva for untreated, good prognosis patients with advanced non-small cell lung cancer

Conditions: Lung Cancer

Summary: this study will evaluate tarceva in a selected population of patients with untreated advanced non-small cell lung cancer who are anticipated to have a relatively good (indolent) prognosis based on clinical criteria. it is anticipated that selection will enrich for tumor characteristic that are likely to be benefited by egfr inhibitor treatment (survival greater than 90 days). the goal of this strategy is to provide a less toxic, oral treatment for patients with advanced nsclc that will not interfere with patients receiving chemotherapy at some point in the future and may prolong the time to chemotherapy related progression. patients will remain on study until disease progresses, a decline in performance status, if patient cannot tolerate the side effects or develops symptoms requiring conventional chemotherapy.

primary objective to determine time to chemotherapy progression (ie includes time on tarceva monotherapy and chemotherapy) in advanced nsclc secondary objectives to evaluate survival and response rate associated with tarceva treatment to study the frequency of symptom improvement (lung cancer subscale)

Eligibility criteria:
inclusion criteria: * performance status 0-1. * weight loss \< 10% in preceding 3 months * age 18 years and older. * adjuvant chemotherapy allowed if \> 6 months from protocol entry * adequate organ function * liver enzymes \< 2x normal, bilirubin = normal * oxygen saturation\> 89% on room air unless chronically oxygen dependent (not cancer related) * creatinine \<2.0 mg exclusion criteria: * not pregnant or lactating. * no clinical brain metastases * no prior chemotherapy for systemic disease * imminent need for chemotherapy for impending organ dysfunction is not allowed
the seatbelt intervention study

Conditions: High Risk Population of Part-time Seatbelt Users

Summary: the study will use a randomized controlled design testing the effectiveness of the following intervention: (i) intervener brief intervention (ibi) vs. (ii) enhanced usual care (euc). the study will identify children ages 2-14 at a pediatric trauma center. children and their parents who agree to participate in the study will then complete a screening survey to identify part time seatbelt use. those who screen positive will complete a more detailed baseline survey and then be randomized to one of two study conditions. at one month, a follow up assessment by telephone will be completed.


Eligibility criteria:
inclusion criteria: * children ages 7-14 and their parent or guardian, at a pediatric trauma center * child admitted to hospital with diagnosis of injury other than sexual assault and suicide * identify as part time seat belt users exclusion criteria: -
clinical evaluation of the needleless® sling

Conditions: Stress Urinary Incontinence

Summary: urinary incontinence which is a major health issue in women affects 30-40% of older women. surgical treatments for sui have undergone many modifications in the last century. the needleless sling system is a one incision, minimally invasive, surgical procedure that has had great acceptance in europe and has recently received fda clearance for use in the united states. we will evaluate effectiveness and patient reported outcomes for needleless® sling system (neomedic international). this is a prospective, multicenter, registry. up to 150 women will be enrolled from up to 3 registry sites. patients will be evaluated at baseline, peri-operatively, and post-operatively up to 2 months, up to 6 months and at 12 months. effectiveness evaluations will include a standing stress test (objective cure), sandvik questions (subjective cure) \& i-qol (quality of life measure). other evaluations will include type of anesthesia, concurrent surgery, operative time, post-operative pain, length of hospital stay, returning to usual activities, change of lower urinary tract symptoms (bflutssf, voiding diaries), goal achievement and patient satisfaction.


Eligibility criteria:
inclusion criteria: a patient must satisfy the following criteria before entering the study: 1. patient has objective demonstrable signs of stress urinary incontinence (sui), including patients with isd. objective testing includes: standing stress test, urodynamics evaluation, or pad test. 2. patient is age 18 or older. 3. patient had a hysterectomy, tubal ligation or is otherwise incapable of pregnancy, or had a negative pregnancy test prior to study entry and has decided to cease childbearing. 4. patient agrees to participate in the study, including completion of all study-related procedures and evaluations, and documents this agreement by signing the irb/ec-approved informed consent. exclusion criteria: * a patient who meets any of the following criteria will be excluded from participating in the study: 1. patient has an associated or suspected neurological disease. 2. patient is on anti-coagulation therapy. 3. patient has received an investigational drug or device in the past 60 days. 4. patient has an active lesion or present injury to perineum or urethra. 5. patient has a urethral obstruction. 6. patient has a significant cystocele \> ics stage 2. 7. the subject has active infection upon urine dipstick analysis, defined as ≥ +1 leukocytes or ≥ +1 nitrates (must reschedule appointment after uti resolves.) 8. patients with combined pop surgery.
glucagon-like peptide-1 receptor agnoists for the assessment of adrenal function

Conditions: Healthy Volunteer Study; HPA; Cortisol Deficiency; Adrenal Insufficiency

Summary: this study aims to investigate the effects of a single dose of the glucagon-like 1 receptor agonist semaglutdie/rybelsus on the hypothalamo-pituitary-adrenal axis, thus cortisol levels and other stresshormones in healthy males.


Eligibility criteria:
inclusion criteria: * healthy male volunteers aged 18-60 years * bmi 18.5-30 kg/m2 * no regular medication exclusion criteria: * participation in a trial with investigational drugs within 30 days * vigorous physical exercise within 24 hours before the study participation * alcohol intake within 24 hours before the study participation * a history of intake of glucocorticoids or glp-1 ra within the last 8 weeks. * known allergy towards glp-1 ra

Keywords: hypothalamo-pituitary-adrenal axis healthy volunteers glucagon-like peptide-1 receptor agonists glp-1 receptor agnoists semaglutide adrenal insufficiency hpa axis adrenal function testing
systemic transthyretin amyloidosis: carpal tunnel syndrome in a portuguese population

Conditions: Transthyretin Amyloidosis; Carpal Tunnel Syndrome

Summary: systemic transthyretin amyloidosis is an aging-related disorder. it is usually associated with cardiac disease but also extends to other organs. recent studies found that idiopathic carpal tunnel syndrome patients may have amyloid deposition in tenosynovial tissue. the main aims of this project are the characterization of the association between idiopathic carpal tunnel syndrome and transthyretin amyloidosis and its evaluation as a predictive factor of cardiac amyloidosis


Eligibility criteria:
inclusion criteria: . patients aged ≥ 60 years old with symptomatic idiopathic carpal tunnel syndrome or other hand surgery indications. exclusion criteria: . diabetes mellitus, hypothyroidism, hemodialysis, rheumatoid arthritis, and other inflammatory arthropathies, multiple myeloma, gout, chondrocalcinosis, colles fracture, space-occupying lesions, and infectious synovitis.
evaluation of vertebroplasty associated with radiotherapy for spine metastases (evar)

Conditions: Osseous Spine Metastases

Summary: a randomized phase iii study of palliative external beam radiotherapy (rtog 97-14) has shown that 8 gy in a single fraction is very effective in providing pain relief, with complete or partial improvement in pain seen in 66% of patients with bone metastases. percutaneous vertebroplasty (pv) is a technique designed to consolidate pathologic vertebral bodies through the injection of orthopaedic cement under fluoroscopic guidance. consolidation provides rapid pain relief to painful vertebral body lesions secondary to osteoporosis, haemangiomas, myeloma and metastatic diseases, with complete or partial improvement in pain seen in 70-85% of patients. to date, no randomized trial has tested the association of vertebroplasty and radiotherapy to enhance pain relief for patients with painful osseous spine metastases. a randomized trial has been designed to determine whether vertebroplasty and radiotherapy (8 gy in a single fraction) provide enhancement pain and narcotic relief compared to radiotherapy alone for patients with painful osseous spine metastases

patients with 1 to 4 painful osseous spine metastases are randomized to 1 of 2 treatment arms: * arm 1: 8 gy in a single fraction * arm 2: 8 gy in a single fraction followed by vertebroplasty of the vertebral bodies, within 14 days after radiotherapy

Eligibility criteria:
inclusion criteria: * osseous spine metastases from squamous cell carcinoma or adenocarcinoma * one to four painful metastases located between the second cervical vertebra and the fifth lumbar vertebra * moderate to severe pain * no spinal cord compression * karnofsky performance status \> 40 exclusion criteria: * previous radiotherapy or surgery * vertebral fracture or any other formal indication of stabilization of the rachis by surgery or vertebroplasty * spinal cord compression * known anomaly of the haemostasis, or needed anticoagulant treatment

Keywords: neoplasm metastasis bone neoplasms pain radiotherapy vertebroplasty combined modality therapy
direct access to mri and neurology referrals for the management of patients with chronic headache.

Conditions: Chronic Headache

Summary: this study aims to evaluate whether direct access from general practitioners (gps) to magnetic resonance imaging (mri) for patients with chronic headache decreases overall nhs costs and increases patient satisfaction compared to clinical practice with referral to neurology services.

headache is the most common symptom reported in the community, affecting more than 90% of the population at some point in their lifetime. despite the low level of referrals to secondary care (as most patients tend to be managed within primary care), the absolute number of headache episodes (due to its high prevalence) makes headache the most frequently listed reason for referral to the neurologist and thus, utilises precious capacity that is severely constrained. in order to support future management of this chronic condition, this study aims to evaluate existing clinical pathways in the management of patients with chronic headache - either referral to the neurology department or direct access to imaging. participants will be followed-up for a period of 12 months after the initial secondary care episode (either an mri scan or neurology appointment). costs from the nhs perspective and self-perceived patient quality of life will be assessed and cost per patient and cost-effectiveness analyses will be performed.

Eligibility criteria:
inclusion criteria: * every patient aged 16 years or over with: i) chronic headache as a primary cause that has lasted ≥ 15 days per month for more than 3 months; and ii) referred from gp practices to gstt, either directly referred to an mri exam or a neurology outpatient appointment. exclusion criteria: * children under the age of 16; * patients with red flags as defined in nice guideline cg150; * patients without chronic primary headache, i.e. a headache that has not persisted for ≥ 15 days per month for more than 3 months * patients with headache referred through the two week wait list; * patients who lack capacity to give consent or participate in the study; * patients not fluent in english; * prisoners; * patients that are already taking part in a clinical trial of an investigational medicinal products (ctimps).
efficacy & safety study of pregabalin to treat chronic prostatitis/chronic pelvic pain syndrome (cp/cpps)

Conditions: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Summary: the purpose of this study is to determine whether pregabalin is an effective treatment for chronic prostatitis/chronic pelvic pain syndrome.

primary objectives 1. to compare six (6) weeks of treatment with pregabalin versus placebo in cp/cpps participants with respect to the primary endpoint in the nih-cpsi 2. to evaluate the safety and tolerability of six (6) weeks of pregabalin in cp/cpps participants design eligible participants will receive either pregabalin or placebo, randomly assigned at a ratio of 2:1. study treatment will be for 6 weeks with dose starting at 150mg going up to 300mg and finally to 600mg daily, to maximum tolerated dose. participants will be advised to take the study medication 3 times per day. there are 3 clinic visits and 2 telephone contacts. participants will be offered optional active treatment for an additional 6 weeks at the end of the first 6 weeks. for those participating in both phases there are a total of 4 clinic visits and 5 telephone contacts.

Eligibility criteria:
inclusion criteria: * participant has signed and dated the appropriate informed consent document. * participant must have had symptoms of discomfort or pain in the pelvic region for at least a three (3) month period within the last six (6) months. exclusion criteria: * participant has continued evidence of facultative gram negative or enterococcus with a value of ≥ 1000 and ≤ 100,000 cfu/ml in mid-stream urine (vb2), as demonstrated by repeat culture obtained no less than seven (7) days post antibiotic treatment. * participant has a calculated creatinine clearance of \<60 ml/min. * participant has a platelet count \<100,000/mm3. * participant is allergic to antiepileptic/antiseizure medications. * participant has a known allergy or sensitivity to pregabalin (lyrica®). * participant is taking thiazolidinedione antidiabetic agents (i.e. rosiglitazone and pioglitazone). * participant has new york heart association class iii or iv congestive heart failure. * participant has a history of thrombocytopenia, or a bleeding diathesis. * participant has a history of prostate, bladder or urethral cancer. * participant has a history of alcohol abuse. * participant has inflammatory bowel disease (such as crohn's disease or ulcerative colitis, but not irritable bowel syndrome). * participant has undergone pelvic radiation or systemic chemotherapy. * participant has undergone intravesical chemotherapy. * participant has been treated with intravesical bcg. * participant has unilateral orchalgia without other pelvic symptoms. * participant has an active urethral stricture. * participant has a neurological disease or disorder affecting the bladder. * participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.
inspiratory muscle training in pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: the aim of this study is to investigate the effective of inspiratory muscle training on respiratory function, exercise capacity, physical activity and quality of life.

pulmonary hypertension (ph) is a condition which is seen with hemodynamic differences, pulmonary vascular resistance and right heart failure. patients with pulmonary hypertension have, dyspnea, physical inactivity, reduced condition and respiratory muscle dysfunction. aerobic exercise programs in patients with pulmonary hypertension are reported to result in improved exercise capacity and endurance of the patients, improvement in who functional class and quality of life, increased peak workload and increased peripheral muscle function. in recent years, few studies have investigated the efficacy of inspiratory muscle training in patients with ph.the aim of this study is to investigate the effective of inspiratory muscle training on respiratory function, exercise capacity, physical activity and quality of life.

Eligibility criteria:
inclusion criteria: * diagnosis of pulmonary hypertension, * nyha functional class i-iv * mip pressure \<80 cm h2o exclusion criteria: * copd * conditions which can limit the assessments * insufficient cooperation

Keywords: pulmonary hypertension inspiratory muscle training functional capacity physical activity
alternate day buprenorphine administration, phase x - 15

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.


Eligibility criteria:
please contact site for information.
the effect of virtual reality glasses on labor pain

Conditions: Labor Pain; Anxiety

Summary: there are different medicinal and non medicinal methods to control labor pain. today, much attention has been on non medicinal methods because of limitations and complications of medical procedures. virtual reality is a new and promising method of diversion of mind that may have an impact on labor pain. this study was conducted to determine the effect of virtual reality on the first stage of labor pain.


Eligibility criteria:
inclusion criteria: * iranian * low risk pregnancy * primipara exclusion criteria: * vision or ear disorders * history of motion sickness or headaches * psychological disease or addiction

Keywords: labor pain virtual reality the first stage of labor pain relief simulator
assessing safety of nipox in peritoneal carcinomatosis of crc

Conditions: Colorectal Cancer

Summary: this study determine the maximal tolerate dose

this study determine the maximal tolerate dose for the patient treated by intraperitoneal chemotherapy in neoadjuvant treatment of peritoneal carcinomatosis of colorectal origin

Eligibility criteria:
inclusion criteria: 1. patients aged over 18 years old 2. histologically confirmed diagnosis of colorectal or appendix cancer 3. peritoneal carcinomatosis of colorectal origin, presumed unresecable or non-optimally resecable, assessed by imaging (ct scan (computed tomography scanner) and mri (magnetic resonance imaging)) or during a previous abdominal surgery 4. peritoneal carcinomatosis index \> 17 5. previous adjuvant chemotherapy is allowed 6. one or several lines of chemotherapy are allowed 7. hemoglobin ≥ 10 g/dl (red blood transfusion is allowed if needed), neutrophils ≥ 1.500/mm3, platelets ≥ 100.000/mm3 and white blood cells \> 3000 /mm3 8. total bilirubin ≤ 1.5 upper limit of normal (uln), alt or ast ≤ 3 uln 9. serum creatinine ≤ 1.5 uln ; serum calcium ≥ lln and ≤ 1.2 x unl ; serum magnesium ≥ lln and ≤ 1.2 x unl ; kalemia ≥ lln 10. ecog (eastern cooperative oncology group) \< 1 11. life expectancy higher than 8 weeks 12. negative pregnancy test in women of childbearing potential 13. use of an effective contraceptive method during the whole treatment and up to 6 months after the completion of treatment 14. patients affiliated to a french social security system 15. signed informed consent (ic) obtained before any study specific procedures exclusion criteria: 1. serum uracile ≥ 16 ng/ml 2. extra peritoneal metastatic disease (except ovarian metastases and retroperitoneal nodes) 3. patients with anesthetic or medical contraindications to surgery 4. peripheral sensory neuropathy ≥ grade 2 at the time of signing the icf 5. patients previously treated with cytoreduction and followed by an intra-peritoneal chemotherapy within the past 6 months. 6. anticancer therapy (e.g. chemotherapy, radiotherapy, targeted therapy, concomitant systemic immune therapy, or any experimental therapy) within 4 weeks before inclusion 7. history or presence of other cancer within the past 5 years (except adequately treated in situ carcinoma of the cervix and non-melanoma skin cancer) 8. pregnant or breastfeeding women 9. known positive test for human immunodeficiency virus (hiv), hepatitis b or c virus or patients with untreated serious infections 10. participation in another clinical trial within 30 days prior to study entry 11. legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study 12. ecg with a qt/qtc interval higher than 450 ms for men and higher than 470 ms for women